Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01637272 · ClinicalTrials.gov registry record · Phase 2
Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome
A Phase 2 study of Dumping Syndrome, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 17
- Study locations
NCT01637272 is a Phase 2 study of Dumping Syndrome that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 43 participants. The trial reports 17 study locations across 8 states.
The verdict
NCT01637272, a Phase 2 study of Dumping Syndrome, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 17
- Study locations
Study Summary
multi-center, phase II study evaluating efficacy, safety and pharmacokinetics of pasireotide in patients with dumping syndrome
Conditions Studied
Interventions
- DRUG SOM230
Study Locations (17)
Other
- Novartis Investigative Site - Brussels
- Novartis Investigative Site - Ghent
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Pessac
- Novartis Investigative Site - Pierre-Bénite
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Würzburg
- Novartis Investigative Site - Groningen
California
- Ximed Center for Weight Management Ximed Research - La Jolla
- Stanford University Medical Center SC - SOM230X2203 - Stanford
Minnesota
- Mayo Clinic - Rochester Mayo MN - Rochester
New York
- Montefiore Medical Center CLCZ696B2320 - The Bronx
Texas
- Texas Tech University Health Science Center - El Paso
Virginia
- Virginia Endocrinology Research SC - Chesapeake
Belgium
- Novartis Investigative Site - Bruges
Netherlands
- Novartis Investigative Site - Utrecht
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2013-01-08 |
| Est. Completion | 2015-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01637272
The ClinicalTrials.gov registry entry for NCT01637272 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dumping Syndrome appearing as the primary indexed condition, and to 1 intervention - of which SOM230 is the first listed.
NCT01637272 reports 17 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01637272 about?
NCT01637272 is a clinical study titled "Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome". multi-center, phase II study evaluating efficacy, safety and pharmacokinetics of pasireotide in patients with dumping syndrome
What is the current status of trial NCT01637272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2013-01-08. Estimated completion is 2015-08-07.
What conditions does trial NCT01637272 study?
This clinical trial studies the following conditions: Dumping Syndrome.
What interventions are being tested in trial NCT01637272?
The interventions under investigation include: SOM230 (DRUG).
Who is sponsoring clinical trial NCT01637272?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01637272 being conducted?
This trial has 17 study locations across California, Minnesota, New York, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.